Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo. (Funded by Novo Nordisk; REDEFINE 1 ClinicalTrials.gov number, NCT05567796.).
Authors
- Eva Winning Lehmann (ORCID: https://orcid.org/0000-0002-0880-8798)
- Cristina Contreras (ORCID: https://orcid.org/0000-0002-7015-7922)
- Thomas A. Wadden (ORCID: https://orcid.org/0000-0002-0438-4609)
- W. Timothy Garvey (ORCID: https://orcid.org/0000-0003-0822-0860)
- Paolo Sbraccia (ORCID: https://orcid.org/0000-0001-9634-1501)
- John P.H. Wilding (ORCID: https://orcid.org/0000-0003-2839-8404)
- Kirsi Hannele Pietiläinen (ORCID: https://orcid.org/0000-0002-8522-1288)
- Domenica Rubino (ORCID: https://orcid.org/0000-0002-3072-2819)
- Matthias Blüher (ORCID: https://orcid.org/0000-0003-0208-2065)
- Melanie Jane Davies (ORCID: https://orcid.org/0000-0002-9987-9371)
- Niels Zeuthen
Institutions
- University of Rome Tor Vergata (IT)
- University of Helsinki (FI)
- University of Liverpool (GB)
- University of Leicester (GB)
- Novo Nordisk (Denmark) (DK)
- Helsinki University Hospital (FI)
- Helmholtz Zentrum München (DE)
- University of Alabama at Birmingham (US)
- Policlinico Tor Vergata (IT)
- Washington Center for Weight Management and Research (US)
- NIHR Leicester Biomedical Research Centre (GB)
- University of Pennsylvania (US)
- Leipzig University (DE)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-06-22
- DOI
- https://doi.org/10.1056/nejmoa2502081
- Citations
- 97
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 135.27
Funders
- Novo Nordisk